This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mustafa, F.
Right arrow Articles by Dudley, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mustafa, F.
Right arrow Articles by Dudley, J. P.

 Previous Article  |  Next Article 

Journal of Virology, March 2003, p. 3866-3870, Vol. 77, No. 6
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.6.3866-3870.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

The Type B Leukemogenic Virus Truncated Superantigen Is Dispensable for T-Cell Lymphomagenesis

Farah Mustafa,1,{dagger} Sanchita Bhadra,1 Dennis Johnston,2 Mary Lozano,1 and Jaquelin P. Dudley1*

Section of Molecular Genetics and Microbiology and Institute for Cellular and Molecular Biology, the University of Texas at Austin, Austin, Texas 78712,1 Department of Biomathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 770302

Received 9 October 2002/ Accepted 20 December 2002


arrow
ABSTRACT
 
Type B leukemogenic virus (TBLV) is a variant of mouse mammary tumor virus (MMTV) that causes T-cell lymphomas in mice. We have constructed a TBLV-MMTV hybrid, pHYB-TBLV, in which 756 bp of the C3H MMTV long terminal repeat (LTR) was replaced with 438 bp of the TBLV LTR. Intraperitoneal injection of pHYB-TBLV transfectants consistently resulted in T-cell lymphomas in 50% of injected weanling BALB/c mice with an average latency period of 5.7 (± 1.5) months. Transfectants of pHYB-TBLV containing a double-frameshift mutation in the truncated superantigen gene (sag) induced T-cell lymphomas with similar incidences, latency periods, and phenotypes, suggesting that cis-acting elements in the TBLV LTR determine disease specificity.


arrow
TEXT
 
Mouse mammary tumor virus (MMTV) is a slow-acting oncogenic retrovirus that causes mammary tumors in mice after a long period (6 to 9 months) (1, 29). An MMTV variant, type B leukemogenic virus (TBLV), has been demonstrated to cause thymic lymphomas with a short latency period (1.5 to 2 months) when injected intrathymically into neonatal mice (2). Compared to MMTV, TBLV has a deletion of 443 nucleotides and a substitution of 124 nucleotides in the U3 region of the long terminal repeat (LTR) (3). This deletion removes a negative regulatory element (NRE) present in the MMTV LTR (17-19, 23, 36, 37), which has been implicated in tissue-specific MMTV expression (6, 30). The substitution creates a triplication of a 62-bp element comprised of sequences flanking the deletion (3) (Fig. 1A).



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 1. Construction and characterization of hybrid MMTV-TBLV proviral clones. (A) Diagram of parental and hybrid MMTV clones. The pHYB-MTV plasmid contains a hybrid between Mtv1 and C3H MMTV. A white box indicates the region upstream of the EcoRI site that is derived from Mtv1. The region downstream of the EcoRI site is derived from exogenous C3H MMTV (31) and is shown as a stippled box, except for the C3H MMTV NRE (black box) that is missing in TBLV. TBLV also contains a triplication of sequences surrounding the MMTV NRE deletion, creating a T-cell enhancer (21). The approximate positions of the viral structural genes are shown, and the LTRs are represented by the larger boxes at the ends of the provirus. The sag genes are designated by boxes above the proviral constructs. The Sag ORF in the TBLV LTR is truncated due to deletion and substitution mutations, yielding a putative Sag protein of 165 amino acids. A mutant TBLV hybrid provirus, pHYB-TBLVsagDFS, that contained two frameshift mutations at the AvrII and ClaI sites in the sag coding sequence (indicated by arrows) was constructed. These mutations would allow translation of only 17 amino acid residues. A 1.5-kb XhoI fragment from pUHD15-1-Hygro(-) provided by Paul Bates (University of Pennsylvania School of Medicine) was inserted into the NheI site of all constructs to provide hygromycin resistance. Details of constructions are available on request. aa, amino acids. (B) Western blotting of Jurkat cells stably transfected with proviruses containing the wild-type TBLV LTR or the TBLV LTR containing two frameshift mutations in the sag gene. Jurkat cells were transfected with various constructs by using Superfect (Qiagen, Valencia, Calif.) according to the manufacturer's directions and were selected in 0.2 mg of hygromycin per ml. Each lane contained 100 µg of cellular lysate, and viral protein expression was detected by using antibody specific for MMTV CA protein (Anti-Gag) (upper panel). Arrows indicate processed and unprocessed forms of the Gag protein. Lysates from untransfected Jurkat cells are shown for comparison. Western blots were performed as previously described (26). The same amounts of cellular lysates (50 µg) were incubated with antibodies specific for actin (Anti-Actin) (lower panel) as a control for protein loading on the gel. (C) Extracellular virus production from transfected Jurkat cells. Various amounts of cell supernatants from pHYB-TBLV or pHYB-TBLVsagDFS transfectants were analyzed by Western blotting with antiserum specific for MMTV CA protein and compared to virus production from the TBLV-induced lymphoma, 485-10 (11).

The LTR deletion and substitution also truncate the open reading frame (ORF) encompassing the U3 region of the LTR (Fig. 1A). This ORF encodes a 37-kDa, type II transmembrane glycoprotein known as superantigen (Sag) that functions in the milk-borne transmission of MMTV (1, 7, 9, 10, 16) by the stimulation of T cells through the T-cell receptor (TCR) (33, 35). The truncated Sag protein encoded in the TBLV LTR lacks the entire C-terminal region that interacts with the TCR, yet it retains the transmembrane region, a part of the extracellular region that includes the five glycosylation sites, a single proteolytic processing site, and the major histocompatibility complex class II protein binding motif (12, 20). This study shows that the truncated TBLV Sag protein is dispensable for virally induced T-cell lymphomas.

A 438-bp region of the TBLV LTR alters MMTV disease specificity. Earlier studies showed that the tropism of the MMTV hybrid provirus pHYB-MTV (31) can be altered by replacement of the 3' LTR with that from thymotropic MMTVs (34). However, these studies did not distinguish between the activity of the truncated Sag protein and that of the cis-acting elements in the LTRs. Therefore, TBLV-specific sequences from the ClaI-to-SstI region in the LTR (438 bp), including the T-cell-specific enhancer (21), were obtained by PCR and used to replace 756 bp from the ClaI-to-SstI region of the pHYB-MTV 3' LTR. Subsequently, Jurkat T cells stably transfected with pHYB-TBLV were derived with the assumption that these cells would express high levels of HYB-TBLV, thus allowing high-efficiency infection and tumorigenesis in mice. Jurkat cells were also transfected with pHYB-TBLV that had been modified by the insertion of two frameshift mutations in the truncated sag gene (pHYB-TBLVsagDFS). Transfected cells were then tested for expression of the Gag CA protein by Western blotting. Comparable amounts of viral proteins from the two constructs were detectable in cell lysates (Fig. 1B) and in culture supernatants (Fig. 1C). Since the frameshift mutations also lie within the transcriptional regulatory sequence, we inserted the 3' LTR from pHYB-TBLVsagDFS and pHYB-TBLV into a luciferase expression vector (32) for transient-transfection experiments in Jurkat cells as described previously (21). No significant difference between the luciferase activities of the two LTRs was observed (data not shown).

Subsequently, 2 x 107 Jurkat cells stably expressing HYB-TBLV or HYB-TBLVsagDFS were injected intraperitoneally into weanling BALB/cJ mice. Injection of HYB-TBLV transfectants resulted in tumors in 50% of the mice with a latency period of 5.7 (± 1.5) months (mean [± standard deviation]), whereas mice receiving HYB-TBLVsagDFS transfectants developed T-cell lymphomas with a 60% incidence and an average latency period of 4.8 (± 0.6) months (Table 1) (P > 0.05). Expression of HYB-TBLV or the sag frameshift mutant in these tumors was confirmed by reverse transcription-PCR and sequencing as described by Mustafa et al. (26) (data not shown). These results revealed that an ~440-bp region from the TBLV LTR was sufficient to alter MMTV disease tropism and that the truncated TBLV Sag protein was not essential for the development of virally induced tumors.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Incidence and latency of tumors induced by clonal TBLV proviruses after injection of transfected Jurkat T cells

Similar clonalities and phenotypes of HYB-TBLV and HYB-TBLVsagDFS-induced T-cell lymphomas. To determine whether the phenotypes of T-cell lymphomas induced by the wild-type (HYB-TBLV) and the mutated (HYB-TBLVsagDFS) viruses were similar, we analyzed the tumor cell populations by flow cytometry (Table 2). Most tumors had a high percentage of Thy1.2+ cells, thereby confirming the T-cell origin of the cells. The Thy1.2+ cell populations were heterogeneous with respect to the surface distribution of CD4 and CD8 markers, but this distribution was not significantly different for the two groups. The tumors were not outgrowths of the originally injected cells since the antibodies used for cell surface staining did not react with Jurkat cells.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Comparison of cell surface markers on lymphomas induced by HYB-TBLV and HYB-TBLVsagDFS in adult BALB/c micea

To analyze the clonality of thymic lymphomas induced by the wild-type and sag frameshift TBLV strains, TCR ß and {gamma} chain rearrangements were analyzed by Southern blotting (Fig. 2). Most of the tumors induced by either virus showed rearrangement of both TCR chains, and many tumors had significant clonal populations. Therefore, the tumors induced by the wild-type and mutated TBLV hybrid proviruses were very similar and comparable to tumors induced by intrathymic injection of TBLV virions into newborn mice (8, 24, 25). These results, combined with cell surface analysis, suggest that the tumors were oligoclonal.



View larger version (47K):
[in this window]
[in a new window]
  		FIG. 2. Analysis of T-cell lymphomas induced by HYB-TBLV and HYB-TBLVsagDFS for TCR rearrangements. (A) Southern blotting for TCR ß chain rearrangements. (B) Southern blotting for TCR {gamma} chain rearrangements. Tumors 13 and 18 were induced by HYB-TBLV, whereas tumors 1, 2, 3, 6, 8, 17, and 21 were induced by HYB-TBLVsagDFS. Additional tumors induced by wild-type TBLV have been characterized previously (22, 24). Digestion of liver DNA from uninfected animals was used to show the DNA fragments that were derived from the unrearranged TCR genes (arrows). Genomic DNA (15 µg) was digested with HindIII, separated on 0.8% agarose gels, transferred to nitrocellulose, and hybridized as previously described (22). Probes p86T5ß (for TCR ß chain) (13) and C{gamma}1.2 (for TCR {gamma} chain) (15) were used for hybridization in panels A and B, respectively.

Lack of requirement for the truncated TBLV Sag during tumorigenesis. Intrathymic injection with tissue culture supernatant from a TBLV-induced T-cell lymphoma line, 485-10, produces T-cell lymphomas in 90% of injected animals (2, 4, 5, 28). The disadvantages of this method are that these virus preparations are uncloned and heterogeneous (our unpublished data). Our clonal TBLV preparations were not injected into newborn mice, but the lower incidence and longer latency period of TBLV-induced tumors in the present study might be explained in two ways. First, since the thymus starts to regress in adult mice, less thymic tissue is available for TBLV infection and random insertions that lead to tumors (8, 27). Second, the route of infection may influence the efficiency of tumorigenesis. In previous experiments, culture supernatants were used to introduce TBLV intrathymically, thus directly inoculating the target for oncogenesis, whereas TBLV-expressing Jurkat T cells were introduced into the mouse peritoneum and must have been transmitted to thymocytes by an unknown mechanism. Inoculations of Jurkat cell transfectants into newborn mice may provide more efficient cell-to-cell transmission than injections of virions, which have given erratic results (unpublished observations).

The truncated Sag protein was not required for virally induced T-cell lymphomas in adult BALB/c mice when transfected Jurkat cells were used for TBLV infection (Table 2). This result may be specific for this route of infection, or, alternatively, the Sag proteins expressed from the endogenous MMTVs in BALB/c mice may complement the sag-null virus. However, it appears likely that the truncated Sag protein has no role in TBLV-induced tumors and that the loss of the NRE and/or other cis-acting elements is responsible for altering the viral disease specificity (14). The development of a cloned TBLV provirus provides us with a valuable tool for molecular dissection of the elements required for changes in MMTV disease specificity.


arrow
ACKNOWLEDGMENTS
 
This work was supported by R01 grants CA34780 and CA77760 from the National Institutes of Health.

We thank members of the Dudley lab for useful comments on the manuscript.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Section of Molecular Genetics and Microbiology and Institute for Cellular and Molecular Biology, The University of Texas at Austin, 100 W. 24th St., Austin, TX 78705. Phone: (512) 471-8415. Fax: (512) 471-7088. E-mail: jdudley{at}uts.cc.utexas.edu. Back

{dagger} Present address: Department of Medical Microbiology, Faculty of Medicine and Health Sciences, The United Arab Emirates (UAE) University, Al Ain, United Arab Emirates. Back


arrow
REFERENCES
 
    1
  1. Acha-Orbea, H., and H. R. MacDonald. 1995. Superantigens of mouse mammary tumor virus. Annu. Rev. Immunol. 13:459-486.[CrossRef][Medline]
    2. 2
  2. Ball, J. K., and G. A. Dekaban. 1987. Characterization of early molecular biological events associated with thymic lymphoma induction following infection with a thymotropic type-B retrovirus. Virology 161:357-365.[CrossRef][Medline]
    3. 3
  3. Ball, J. K., H. Diggelmann, G. A. Dekaban, G. F. Grossi, R. Semmler, P. A. Waight, and R. F. Fletcher. 1988. Alterations in the U3 region of the long terminal repeat of an infectious thymotropic type B retrovirus. J. Virol. 62:2985-2993.[Abstract/Free Full Text]
    4. 4
  4. Ball, J. K., and J. A. McCarter. 1971. Repeated demonstration of a mouse leukemia virus after treatment with chemical carcinogens. J. Natl. Cancer Inst. 46:751-762.
    5. 5
  5. Ball, J. K., and J. A. McCarter. 1979. Biological characterization of a leukemogenic virus isolated from the CFW mouse. Cancer Res. 39:3080-3088.[Abstract/Free Full Text]
    6. 6
  6. Bramblett, D., C.-L. L. Hsu, M. Lozano, K. Earnest, C. Fabritius, and J. Dudley. 1995. A redundant nuclear protein binding site contributes to negative regulation of the mouse mammary tumor virus long terminal repeat. J. Virol. 69:7868-7876.[Abstract]
    7. 7
  7. Brandt-Carlson, C., and J. S. Butel. 1991. Detection and characterization of a glycoprotein encoded by the mouse mammary tumor virus long terminal repeat gene. J. Virol. 65:6051-6060.[Abstract/Free Full Text]
    8. 8
  8. Broussard, D. R., J. A. Mertz, M. Lozano, and J. P. Dudley. 2002. Selection for c-myc integration sites in polyclonal T-cell lymphomas. J. Virol. 76:2087-2099.[Abstract/Free Full Text]
    9. 9
  9. Choi, Y., J. W. Kappler, and P. Marrack. 1991. A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus. Nature 350:203-207.[CrossRef][Medline]
    10. 10
  10. Choi, Y., P. Marrack, and J. W. Kappler. 1992. Structural analysis of a mouse mammary tumor virus superantigen. J. Exp. Med. 175:847-852.[Abstract/Free Full Text]
    11. 11
  11. Dekaban, G. A., and J. K. Ball. 1984. Integration of type B retroviral DNA in virus-induced primary murine thymic lymphomas. J. Virol. 52:784-792.[Abstract/Free Full Text]
    12. 12
  12. Denis, F., N. H. Shoukry, M. Delcourt, J. Thibodeau, N. Labrecque, H. McGrath, J. S. Munzer, N. G. Seidah, and R.-P. Sékaly. 2000. Alternative proteolytic processing of mouse mammary tumor virus superantigens. J. Virol. 74:3067-3073.[Abstract/Free Full Text]
    13. 13
  13. Epstein, R., N. Roehm, P. Marrack, J. Kappler, M. Davis, S. Hedrick, and M. Cohn. 1985. Genetic markers of the antigen-specific T cell receptor locus. J. Exp. Med. 161:1219-1224.[Abstract/Free Full Text]
    14. 14
  14. Hsu, C.-L. L., C. Fabritius, and J. Dudley. 1988. Mouse mammary tumor virus proviruses in T-cell lymphomas lack a negative regulatory element in the long terminal repeat. J. Virol. 62:4644-4652.[Abstract/Free Full Text]
    15. 15
  15. Iwamoto, A., F. Rupp, P. S. Ohashi, C. L. Walker, H. Pircher, R. Joho, H. Hengartner, and T. W. Mak. 1986. T cell-specific gamma genes in C57BL/10 mice. Sequence and expression of new constant and variable region genes. J. Exp. Med. 163:1203-1212.[Abstract/Free Full Text]
    16. 16
  16. Krummenacher, C., and H. Diggelmann. 1993. The mouse mammary tumor virus long terminal repeat encodes a 47 kDa glycoprotein with a short half-life in mammalian cells. Mol. Immunol. 30:1151-1157.[CrossRef][Medline]
    17. 17
  17. Lee, J. W., P. G. Moffitt, K. L. Morley, and D. O. Peterson. 1991. Multipartite structure of a negative regulatory element associated with a steroid hormone-inducible promoter. J. Biol. Chem. 266:24101-24108.[Abstract/Free Full Text]
    18. 18
  18. Liu, J., A. Barnett, E. J. Neufeld, and J. P. Dudley. 1999. Homeoproteins CDP and SATB1 interact: potential for tissue-specific regulation. Mol. Cell. Biol. 19:4918-4926.[Abstract/Free Full Text]
    19. 19
  19. Liu, J., D. Bramblett, Q. Zhu, M. Lozano, R. Kobayashi, S. R. Ross, and J. P. Dudley. 1997. The matrix attachment region-binding protein SATB1 participates in negative regulation of tissue-specific gene expression. Mol. Cell. Biol. 17:5275-5287.[Abstract]
    20. 20
  20. McMahon, C. W., L. Y. Bogatzki, and A. M. Pullen. 1997. Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells. Virology 228:161-170.[CrossRef][Medline]
    21. 21
  21. Mertz, J. A., F. Mustafa, S. Meyers, and J. P. Dudley. 2001. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. J. Virol. 75:2174-2184.[Abstract/Free Full Text]
    22. 22
  22. Meyers, S., P. D. Gottlieb, and J. P. Dudley. 1989. Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo. J. Immunol. 142:3342-3350.[Abstract]
    23. 23
  23. Morley, K. L., M. G. Toohey, and D. O. Peterson. 1987. Transcriptional repression of a hormone-responsive promoter. Nucleic Acids Res. 15:6973-6989.[Abstract/Free Full Text]
    24. 24
  24. Mueller, R. E., J. K. Ball, and F. P. Chan. 1989. Characterization of cell markers in type B retroviral-induced thymic lymphomas. I. Surface antigen phenotype and karyotype in developing and primary lymphomas. Leuk. Res. 13:553-559.[CrossRef][Medline]
    25. 25
  25. Mueller, R. E., J. K. Ball, and F. P. Chan. 1989. Characterization of cell markers in type B retroviral-induced thymic lymphomas. II. Surface antigen phenotype, karyotype and proviral integration pattern in cultured lymphoma cells and cloned lines. Leuk. Res. 13:561-571.[CrossRef][Medline]
    26. 26
  26. Mustafa, F., M. Lozano, and J. P. Dudley. 2000. C3H mouse mammary tumor virus superantigen function requires a splice donor site in the envelope gene. J. Virol. 74:9431-9440.[Abstract/Free Full Text]
    27. 27
  27. Rajan, L., D. Broussard, M. Lozano, C. G. Lee, C. A. Kozak, and J. P. Dudley. 2000. The c-myc locus is a common integration site in type B retrovirus-induced T-cell lymphomas. J. Virol. 74:2466-2471.[Abstract/Free Full Text]
    28. 28
  28. Roder, J. C., L. Tyler, S. K. Singhal, and J. K. Ball. 1978. Are T-cell lymphomas immunocompetent? Nature 273:540-541.[CrossRef][Medline]
    29. 29
  29. Ross, S. R. 2000. Using genetics to probe host-virus interactions; the mouse mammary tumor virus model. Microbes Infect. 2:1215-1223.[CrossRef][Medline]
    30. 30
  30. Ross, S. R., C.-L. Hsu, Y. Choi, E. Mok, and J. P. Dudley. 1990. Negative regulation in correct tissue-specific expression of mouse mammary tumor virus in transgenic mice. Mol. Cell. Biol. 10:5822-5829.[Abstract/Free Full Text]
    31. 31
  31. Shackleford, G. M., and H. E. Varmus. 1988. Construction of a clonable, infectious, and tumorigenic mouse mammary tumor virus provirus and a derivative genetic vector. Proc. Natl. Acad. Sci. USA 85:9655-9659.[Abstract/Free Full Text]
    32. 32
  32. van Zonneveld, A. J., S. A. Curriden, and D. J. Loskutoff. 1988. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc. Natl. Acad. Sci. USA 85:5525-5529.[Abstract/Free Full Text]
    33. 33
  33. Wrona, T. J., M. Lozano, A. A. Binhazim, and J. P. Dudley. 1998. Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen. J. Virol. 72:4746-4755.[Abstract/Free Full Text]
    34. 34
  34. Yanagawa, S.-I., K. Kakimi, H. Tanaka, A. Murakami, Y. Nakagawa, Y. Kubo, Y. Yamada, H. Hiai, K. Kuribayashi, T. Masuda, and A. Ishimoto. 1993. Mouse mammary tumor virus with rearranged long terminal repeats causes murine lymphomas. J. Virol. 67:112-118.[Abstract/Free Full Text]
    35. 35
  35. Yazdanbakhsh, K., C. G. Park, G. M. Winslow, and Y. Choi. 1993. Direct evidence for the role of COOH terminus of mouse mammary tumor virus superantigen in determining T cell receptor Vß specificity. J. Exp. Med. 178:737-741.[Abstract/Free Full Text]
    36. 36
  36. Zhu, Q., and J. P. Dudley. 2002. CDP binding to multiple sites in the mouse mammary tumor virus long terminal repeat suppresses basal and glucocorticoid-induced transcription. J. Virol. 76:2168-2179.[Abstract/Free Full Text]
    37. 37
  37. Zhu, Q., K. Gregg, M. Lozano, J. Liu, and J. P. Dudley. 2000. CDP is a repressor of mouse mammary tumor virus expression in the mammary gland. J. Virol. 74:6348-6357.[Abstract/Free Full Text]

Journal of Virology, March 2003, p. 3866-3870, Vol. 77, No. 6
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.6.3866-3870.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mertz, J. A., Chadee, A. B., Byun, H., Russell, R., Dudley, J. P. (2009). Mapping of the Functional Boundaries and Secondary Structure of the Mouse Mammary Tumor Virus Rem-responsive Element. J. Biol. Chem. 284: 25642-25652 [Abstract] [Full Text]  
  • Bhadra, S., Lozano, M. M., Dudley, J. P. (2009). BALB/Mtv-Null Mice Responding to Strong Mouse Mammary Tumor Virus Superantigens Restrict Mammary Tumorigenesis. J. Virol. 83: 484-488 [Abstract] [Full Text]  
  • Voisset, C., Weiss, R. A., Griffiths, D. J. (2008). Human RNA "Rumor" Viruses: the Search for Novel Human Retroviruses in Chronic Disease. Microbiol. Mol. Biol. Rev. 72: 157-196 [Abstract] [Full Text]  
  • Rouault, F., Nejad Asl, S. B., Rungaldier, S., Fuchs, E., Salmons, B., Gunzburg, W. H. (2007). Promoter Complex in the Central Part of the Mouse Mammary Tumor Virus Long Terminal Repeat. J. Virol. 81: 12572-12581 [Abstract] [Full Text]  
  • Mertz, J. A., Kobayashi, R., Dudley, J. P. (2007). ALY Is a Common Coactivator of RUNX1 and c-Myb on the Type B Leukemogenic Virus Enhancer. J. Virol. 81: 3503-3513 [Abstract] [Full Text]  
  • Mertz, J. A., Simper, M. S., Lozano, M. M., Payne, S. M., Dudley, J. P. (2005). Mouse Mammary Tumor Virus Encodes a Self-Regulatory RNA Export Protein and Is a Complex Retrovirus. J. Virol. 79: 14737-14747 [Abstract] [Full Text]  
  • Bhadra, S., Lozano, M. M., Dudley, J. P. (2005). Conversion of Mouse Mammary Tumor Virus to a Lymphomagenic Virus. J. Virol. 79: 12592-12596 [Abstract] [Full Text]  
  • Etkind, P. R., Stewart, A. F. R., Dorai, T., Purcell, D. J., Wiernik, P. H. (2004). Clonal Isolation of Different Strains of Mouse Mammary Tumor Virus-Like DNA Sequences from Both the Breast Tumors and Non-Hodgkin's Lymphomas of Individual Patients Diagnosed with Both Malignancies. Clin. Cancer Res. 10: 5656-5664 [Abstract] [Full Text]  
  • Zhu, Q., Maitra, U., Johnston, D., Lozano, M., Dudley, J. P. (2004). The Homeodomain Protein CDP Regulates Mammary-Specific Gene Transcription and Tumorigenesis. Mol. Cell. Biol. 24: 4810-4823 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mustafa, F.
Right arrow Articles by Dudley, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mustafa, F.
Right arrow Articles by Dudley, J. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»